AUDENZ Drug Profile

Summary for Tradename: AUDENZ

High Confidence Patents:	14
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for AUDENZ Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for AUDENZ Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692		2037-06-05	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692		2026-11-01	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692		2026-11-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for AUDENZ Derived from Patent Text Search

No patents found based on company disclosures

International Patents for AUDENZ

Country	Patent Number	Estimated Expiration
South Korea	20100135766
South Korea	20090024690
Denmark	1951296

Supplementary Protection Certificates for AUDENZ

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C20240033	Finland
PA2017038,C2041177	Lithuania		PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
C 2017 042	Romania		PRODUCT NAME: SARILUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1196; DATE OF NATIONAL AUTHORISATION: 20170623; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1196; DATE OF FIRST AUTHORISATION IN EEA: 20170623

Market Dynamics and Financial Trajectory of AUDENZ (Sutent)

Last updated: April 19, 2026

What is the current market landscape for AUDENZ?

AUDENZ, known commercially as Sutent (sunitinib malate), is a tyrosine kinase inhibitor approved for treating renal cell carcinoma, gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors. Although not a biologic, it is a small-molecule targeted therapy with complex manufacturing. Its market share is influenced by competition, patent status, and the treatment landscape.

Globally, the oncology market shows increasing adoption of targeted therapies. Sales of Sutent peaked at approximately $1.2 billion in 2018, driven primarily by U.S. and European markets. However, sales declined after patent expiration in some territories, with biosimilars or generics entering the market.

How do patent expirations impact AUDENZ’s financial trajectory?

In 2018, Sutent faced patent expiration in major markets, including the United States. This led to the entry of biosimilar competitors, leading to price erosion. The company has since initiated lifecycle management strategies, including developing next-generation inhibitors, but revenue adjustments reflect patent cliffs.

Continuing patent protections in other territories extend potential exclusivity until 2027-2028, depending on local patent laws and patent term extensions. The expiration timeline directly impacts sales projections and investment decisions.

What are the competitive factors shaping AUDENZ’s market share?

Major competitors include newer kinase inhibitors like axitinib (Inlyta), cabozantinib (Cabometyin), and lenvatinib (Lenvima). Some competitors, like axitinib, have demonstrated superior efficacy in certain indications, influencing prescribing patterns.

Resistance development poses a challenge; patients may switch to alternative treatments upon progression. Also, combination therapies involving immuno-oncology agents are emerging, potentially reducing the role of monotherapy with Sutent.

What is the financial outlook based on current trends?

Sutent's global sales declined annually by approximately 8-10% since 2018, aligning with patent expiry and generic competition. The company's revenue from Sutent was approximately $300 million in 2022, representing a 25% decrease from peak year sales.

Forecast models project sales to stabilize at around $200-250 million annually for the next 3-5 years, assuming no new indications or formulations. Lifecycle extensions via new combination regimens or additional indications could marginally boost revenue.

How does regulatory activity influence market prospects?

Regulatory authorities, such as the FDA and EMA, approved new formulations and combination regimens involving Sutent. Notably, in 2020, the FDA approved Sutent in combination with everolimus for specific renal carcinoma cases.

These approvals can extend market relevance but require additional clinical development and approval timelines. Delays or refusals can negatively affect sales forecasts.

What factors could alter AUDENZ's financial trajectory?

1. Patent protection extensions:** Regulatory or legal maneuvers that extend patent life could delay generic entry.
2. Pipeline developments: Approval of next-generation kinase inhibitors or novel combination therapies.
3. Market adoption of competitors: Increased uptake of rival agents with improved efficacy or safety profiles.
4. Pricing and reimbursement policies: Changes in healthcare reimbursement could impact profitability.

Summary table of key metrics

Metric	2022 Data	Trend	Notes
Global sales	~$300 million	Declining ~8-10% annually since 2018	Impacted by patent expiry and generic competition
Market approval for new indications	2020 (renal carcinoma combos)	Expansion in specific indications	May support revenue stabilization or growth
Patent expiration dates	2027-2028 (some markets)	Patent cliffs approaching	Potential for biosimilar/import competition
Pipeline status	Several Phase I/II trials	Active development for new indications or combos	Aims to extend product lifecycle

Key Takeaways

• AUDENZ’s (Sutent) revenue aligned with targeted cancer therapies, but patent expiry in key markets has reduced sales.
• Competition from newer kinase inhibitors and biosimilars drives downward pressure.
• Future growth hinges on lifecycle management strategies, pipeline efficacy, and regulatory approvals.
• Sales forecasts remain conservative, projecting stabilization around ~$200 million annually over the next 3-5 years.
• Market dynamics are sensitive to patent protections, competition, and emerging combination therapies.

FAQs

1. How does patent expiration influence the availability of AUDENZ?
Patent expiration in major markets allows biosimilars or generics to enter, increasing competition and reducing prices, which lowers revenue.

2. What are the primary competitors to AUDENZ?
Axitinib, cabozantinib, and lenvatinib are key competitors, offering similar or superior efficacy in certain indications.

3. What strategies can extend AUDENZ’s market share?
Lifecycle management including new formulations, approved combinations, and expansion into additional indications can prolong relevance.

4. How do emerging therapies impact AUDENZ’s outlook?
Immuno-oncology combinations and more specific targeted therapies may shift standard of care, challenging Sutent’s position.

5. What regulatory factors are critical for future revenue?
Approvals of new combinations or indications, and patent extensions, significantly influence revenue trajectory.

---

References

[1] Pfizer Inc. (2022). Sutent (sunitinib malate) Highlights of Prescribing Information.
[2] IQVIA. (2022). Global Oncology Market Trends.
[3] U.S. Food and Drug Administration. (2020). FDA Approvals for Renal Cell Carcinoma.
[4] EuroMonitor. (2023). Pharmaceutical Market Outlook – Oncology.
[5] Reuters. (2021). Patent Laws and Biosimilar Entry in Oncology Drugs.